Contents |
1 Introduction |
2 Simulation Examples |
- Single Oral Dose
- Multiple Oral Dose
- IV Infusion
- Nonlinear Eliminaton
- Two Compartment Model
|
3 Simulations |
I: Introduction to Pharmokinetic
Parameters |
- Elimination Rate Constant (k)
- Volume of Distribution (Vd)
- Half Life (t1/2)
- Total Body Clearance (TBC)
- Area Under the Concentration-Time Curve
- Bioavailability (F)
- First-Order Absorption Rate Constant (ka)
- Dose (D)
|
II: IV Bolus Administration |
- One Compartment Model:
- Single Dose
- Multiple Doses
- Loading Dose and Multiple Doses
- Two Compartment Model:
- Single Dose
- Multiple Doses
- Loading Dose and Multiple Doses
|
III: Oral Administration
|
- One Compartment Model:
- Single Dose
- Multiple Doses
- Loading Dose and Multiple Doses
- Two Compartment Model:
- Single Dose
- Multiple Doses
- Loading Dose and Multiple Doses
|
IV: Multiple Administration
|
- One Compartment Model:
- Multiple IV Doses
- Multiple Oral Doses
- Two Compartment Model:
- Multiple IV Doses
- Multiple Oral Doses
- Multiple IV Doses and MM Elimination
- Multiple Oral Doses and MM Elimination
|
V: Constant Rate IV Infusion
|
- One Compartment Model
- IV Infusion
- Loading Dose and Iv Infusion
- Two Compartment Mode
- IV Infusion
- Loading Dose and IV Infusion
|
VI: Intermittent IV Infusion
|
- One Compartment Model:
- Single IV Infusion
- Multiple Short IV Infusions
- Loading Dose and Multiple IV Infusions
- Two Compartment Model:
- Single IV Infusion
- Multiple Short IV Infusions
- Loading Dose and Multiple IV Infusion
|
VII: Multiple Compartments
|
- Two Compartment Model:
- Single IV Dose
- Multiple IV Doses
- Single Oral Dose
- Multiple Oral Doses
- IV Infusion
- Loading Dose and IV Infusion
- Single IV Dose
- Central and Peripheral Profiles
- Multiple IV Doses - Central and Peripheral Profiles
|
VIII: Nonlinear Elimination
|
- Single IV Dose - Nonlinear Elimination
- Multiple IV Doses - Nonlinear Elimination
- Single Oral Dose - Nonlinear Elimination
- Multiple Oral Doses - Nonlinear Elimination
- MM Elimination In Presence of a Competitive Inhibitor
|